WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has recently announced a memorandum of understanding (MOU) with South Korea-based IntoCell. The collaboration aims to comprehensively work on new toxin linker technology and contract research, development, and production (CRDMO) services.
Under the terms of the agreement, IntoCell will provide its proprietary linker containing ortho hydroxy protected aryl sulfate (OHPAS) and a novel camptothecin toxin called Nexatecans, which is a novel OHPAS camptothecin toxin linker technology. WuXi XDC will contribute by offering a highly integrated one-stop development platform for biologically coupled drugs and end-to-end CRDMO services. Together, they aim to empower their clients to accelerate the discovery of pre-clinical candidate compounds and develop more novel antibody drug conjugates (ADCs) and bio-conjugated drugs.- Flcube.com
